Type I Diabetes

February 6th 2025

COUR Pharmaceuticals is about begin a phase 1b/2a study to assess a therapy for type 1 diabetes that prevents islet cell destruction and triggers a T cell response.

February 1st 2025

In a new study, researchers found that time-in-range for healthy blood sugar could be a viable marker of glycemic control and potentially could be used to predict complications of type 1 diabetes.

January 15th 2025

Sana Biotechnology’s hypoimmune platform enables it to make a series of genetic modifications to cells, rendering the cells invisible to a patient’s immune system.

January 6th 2025

The updated guidelines from the American Diabetes Association emphasize the use of antibody-based screening for type 1 diabetes and recommend that physicians discuss potential use of Tzield, a monoclonal antibody approved to delay the onset of the symptoms of the disease.